title: Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.
abstract: Few therapeutic options are available for mucocutaneous leishmaniasis (MCL). We conducted a randomized open trial to evaluate the efficacy, safety, and tolerance of parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days compared with intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days in patients with moderate MCL in Cuzco, Peru. Cure was defined as complete healing with re-epithelialization within 1 year of follow-up. The trial was stopped after 38 patients were enrolled (17 in the MA group and 21 in the AS group) because of marked differences in response. Study groups were comparable in baseline characteristics. Cure rates were 0/21 in the AS group compared with 8/17 (47%, 95% confidence interval: 23-71%) in the MA group (P < 0.001). Side effects and laboratory abnormalities were mild in both groups. We conclude that parenteral AS given on its own is not effective for MCL in Peru.
authors.affiliation: Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru. allanos@upch.edu.pe
authors.forename: Alejandro
authors.initials: A
authors.lastname: Llanos-Cuentas
authors.forename: Juan
authors.initials: J
authors.lastname: Echevarria
authors.forename: Carlos
authors.initials: C
authors.lastname: Seas
authors.forename: Elsa
authors.initials: E
authors.lastname: Chang
authors.forename: Maria
authors.initials: M
authors.lastname: Cruz
authors.forename: Eugenia
authors.initials: E
authors.lastname: Alvarez
authors.forename: Ernesto
authors.initials: E
authors.lastname: Rosales
authors.forename: Pablo
authors.initials: P
authors.lastname: Campos
authors.forename: Anthony
authors.initials: A
authors.lastname: Bryceson
mesh_terms: D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007263:Infusions, Parenteral; D007892:Leishmania braziliensis / Q000254:growth & development*; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage* / Q000009:adverse effects; D000077485:Meglumine Antimoniate; D009297:Nasal Mucosa / Q000187:drug effects / Q000469:parasitology; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D010303:Paromomycin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010303:Paromomycin; D008536:Meglumine; D000077485:Meglumine Antimoniate